Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 4Carcinoma, Renal Cell 4Recurrence 1Prostatic Hyperplasia 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Kidney Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1

Interventions

aldesleukin 42Sunitinib 39Cyclophosphamide 30Nivolumab 27Everolimus 27pembrolizumab 26Interferon-alpha 25Bevacizumab 22Sorafenib 21Interleukin-2 20fludarabine phosphate 19Filgrastim 18Ipilimumab 17Radiotherapy 16Axitinib 16Peripheral Blood Stem Cell Transplantation 15Gemcitabine 15cabozantinib 14fludarabine 11Radiosurgery 11Doxorubicin 11Carboplatin 11temsirolimus 10Etoposide 9Chemotherapy, Adjuvant 9sargramostim 8belzutifan 8atezolizumab 8Fluorouracil 8pazopanib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Kidney Neoplasms × TroVax × Clear all
NCT00445523 2016-03-17

Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer

The Methodist Hospital Research Institute

Phase 2 Completed
28 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡